BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Ciprofibrate
,
rs7903146
,
LEP
,
calcium channel activity
,
Arthritis
,
Liver
,
Nosology
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
viracept
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the …
The Viracept-EMS case: impact and outlook.
What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Viracept Expanded Access Program
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/L…
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
A Study of Viracept in HIV-Positive Women
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children a…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ